Market Place
Sourcing Support
Cellenkos Announces to Present at ASH on CK0804 in Myelofibrosis
07 Nov 2024 //
PR NEWSWIRE
Neurocrine Presents INGREZZA® Data at Psych Congress 2024
04 Nov 2024 //
PR NEWSWIRE
Neurocrine Presents Data on INGREZZA® for Tardive Dyskinesia
04 Nov 2024 //
PR NEWSWIRE
Neurocrine Presents Data On Chorea Improvements In Huntington`s
30 Sep 2024 //
PR NEWSWIRE
Zydus gains final USFDA approval for Valbenazine Capsules
09 Aug 2024 //
EXPRESSPHARMA
Neurocrine Launches INGREZZA® SPRINKLE For Easier Administration
18 Jul 2024 //
PR NEWSWIRE
Neurocrine founder-CEO Gorman to retire in October
28 May 2024 //
REUTERS
Neurocrine Biosciences` Huntington`s disease drug gets FDA approval
01 May 2024 //
PRESS RELEASE
Neurocrine Biosciences® Presents INGREZZA® (valbenazine) Capsules Interim Data
02 Nov 2023 //
PR NEWSWIRE
Neurocrine Biosciences Announces U.S. FDA Accepts NDA for INGREZZA
14 Sep 2023 //
PR NEWSWIRE
Neurocrine Presents Data at MDS International Congress of Parkinson`s Disease
29 Aug 2023 //
PR NEWSWIRE
Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Capsules Data
28 Aug 2023 //
PR NEWSWIRE
Neurocrine Announces FDA Approval of INGREZZA Capsules for Huntington`s Disease
19 Aug 2023 //
PR NEWSWIRE
Neurocrine Biosciences Presents INGREZZA® (valbenazine) Capsules Data
02 Jun 2023 //
PR NEWSWIRE
Neurocrine Announces Publication of Full KINECT™-HD Results of Valbenazine
19 May 2023 //
PR NEWSWIRE
Lupin gets tentative USFDA approval to market generic valbenazine capsules
27 Mar 2023 //
ECONOMIC TIMES
Neurocrine Bio Presents Data on In Vitro Dissolution Performance of INGREZZA
09 Mar 2023 //
PR NEWSWIRE
Neurocrine Presents Data on Improvements Over Time with Use of INGREZZA
03 Mar 2023 //
PR NEWSWIRE
Neurocrine Biosciences Announces U.S. FDA Accepts sNDA for Valbenazine
22 Dec 2022 //
PRNEWSWIRE
Sandoz`s Generic Valbenazine Tosylate Receives Approval in the U.S.
12 Dec 2022 //
FDA
Teva`s Generic Valbenazine Tosylate Receives Approval in the U.S.
25 Nov 2022 //
FDA
Neurocrine Presents Phase 3 Data for KINECT-HD Study Evaluating Valbenazine
03 Nov 2022 //
PRNEWSWIRE
Zydus gets tentative USFDA approval for Valbenazine capsules
17 Oct 2022 //
HEALTH ET
Zydus` Generic Valbenazine Tosylate Receives Approval in the U.S.
13 Oct 2022 //
FDA
Neurocrine INGREZZA Data on Sustained Treatment Response at Psych Congress 2022
19 Sep 2022 //
PRNEWSWIRE
Neurocrine Biosciences Presents New INGREZZA Data on Tardive Dyskinesia
23 May 2022 //
PRNEWSWIRE
Neurocrine Announces Positive Phase 3 Data for KINECT-HD Study of Valbenazine
07 Dec 2021 //
PRNEWSWIRE
Neurocrine to Present New INGREZZA and ONGENTYS Data at the MDS Congress
10 Sep 2021 //
PRNEWSWIRE
Neurocrine Bioscience to Present Data for Tardive Dyskinesia &Parkinson Disease
03 Sep 2020 //
PRNEWSWIRE
Teva’s weak pipeline hit by Tourette’s drug trial failure
21 Feb 2020 //
PMLIVE
US backs Sanofi’s ‘fast-track’ coronavirus vaccine
19 Feb 2020 //
PMLIVE
Neurocrine, Xenon ink R&D deal targeting rare form of epilepsy
02 Dec 2019 //
BIOPHARMA DIVE
Neurocrine Biosciences Publishes Long-Term INGREZZA® (valbenazine)
12 Nov 2019 //
PR NEWSWIRE
Neurocrine Biosciences to Present Data Analyses on INGREZZA® (valbenazine)
30 Apr 2019 //
PR NEWSWIRE
Neurocrine flags a failure for Tourette syndrome study — shares sink
13 Dec 2018 //
ENDPTS
Neurocrine Biosciences Smacked On Rising Expectations And Fraying Nerves
20 Nov 2018 //
SEEKING ALPHA
As Teva`s Austedo gets more play, doctors are coming around
11 Jun 2018 //
FIERCE PHARMA
After disappointing 2016, new drug approvals roared back to life in 2017
02 Jan 2018 //
FIERCE BIOTECH
